Identification | Back Directory | [Name]
(2R,3S)-3-(tert-Butoxycarbonylamino)-1-chloro-2-hydroxy-4-phenylbutane | [CAS]
162536-40-5 | [Synonyms]
tert-Butyl ((2S,3R)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)carbaMate tert-butyl N-[(2S,3R)-4-chloro-3-hydroxy-1-phenylbutan-2-yl]carbamate (2R,3S)-3-(tert-Butoxycarbonylamino)-1-chloro-2-hydroxy-4-phenylbutane (2R,3S)-N-tert-Butoxycarbonyl-3-amino-1-chloro-2-hydroxy-4-phenylbutane (2R,3S)-1-Chloro-2-hydroxy-3-N-(tert-butoxycarbonyl)amino-4-phenylbutane N-[(1S,2R)-3-Chloro-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid tert-butyl ester Carbamic acid, N-[(1S,2R)-3-chloro-2-hydroxy-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester | [EINECS(EC#)]
923-366-1 | [Molecular Formula]
C15H22ClNO3 | [MOL File]
162536-40-5.mol | [Molecular Weight]
299.79 |
Chemical Properties | Back Directory | [Melting point ]
83-84℃ | [Boiling point ]
460.5±45.0 °C(Predicted) | [density ]
1.153 | [storage temp. ]
Sealed in dry,2-8°C | [pka]
11.92±0.46(Predicted) |
Hazard Information | Back Directory | [Synthesis]
The synthesis of tert-butyl (1S,2S)-(1-benzyl-3-chloro-2-hydroxypropyl)carbamate and (2R,3S)-3-tert-butoxycarbonyl-1-chloro-2-hydroxy-4-phenylbutane was carried out via ruthenium-catalyzed asymmetric hydrogenation using (3S)-3-(tert-butoxycarbonyl)amino-1-chloro-4-phenyl-2-butanone as the starting material. The experiments were catalyzed using different ruthenium ligands under the following reaction conditions: substrate 1 mmol, substrate to catalyst ratio (S/C) of 100:1, solvent 4 mL methanol, and reaction time 20 h (not optimized). The reaction temperature and pressure were adjusted according to the catalyst type, and the results are shown in Table 1.Entry 1 used Ru(S-Xyl-P-Phos)(acac) as the catalyst and was reacted at 50 °C and 1 bar pressure, resulting in a conversion of 51%, with the major product in the (2R,3S)-configuration, and an enantiomeric excess (de) of 82%.Entry 2 used Ru(SP -Phos)Cl2(dmf) as a catalyst at 65 °C and 20 bar pressure resulted in 89% conversion with the same (2R,3S)-configuration as the major product and an enantiomeric excess (de) of 79%. | [References]
[1] Journal of Medicinal Chemistry, 1994, vol. 37, # 12, p. 1758 - 1768 [2] Journal of Medicinal Chemistry, 1994, vol. 37, # 12, p. 1758 - 1768 [3] Journal of Organic Chemistry, 2004, vol. 69, # 21, p. 7344 - 7347 [4] Journal of Organic Chemistry, 2004, vol. 69, # 21, p. 7391 - 7394 [5] Journal of Organic Chemistry, 2004, vol. 69, # 21, p. 7391 - 7394 |
|
|